Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Intangibles (2020 - 2025)

Historic Intangibles for Strata Critical Medical (SRTAW) over the last 6 years, with Q3 2025 value amounting to $49.8 million.

  • Strata Critical Medical's Intangibles rose 25648.06% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 25648.06%. This contributed to the annual value of $8.0 million for FY2024, which is 6118.72% down from last year.
  • As of Q3 2025, Strata Critical Medical's Intangibles stood at $49.8 million, which was up 25648.06% from $13.6 million recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's Intangibles peaked at $49.8 million during Q3 2025, and registered a low of $1.5 million during Q2 2021.
  • For the 5-year period, Strata Critical Medical's Intangibles averaged around $25.7 million, with its median value being $21.6 million (2022).
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 227223.26% in 2021, then crashed by 6881.39% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Intangibles stood at $24.4 million in 2021, then skyrocketed by 89.86% to $46.4 million in 2022, then plummeted by 55.74% to $20.5 million in 2023, then tumbled by 61.19% to $8.0 million in 2024, then skyrocketed by 524.74% to $49.8 million in 2025.
  • Its Intangibles stands at $49.8 million for Q3 2025, versus $13.6 million for Q2 2025 and $13.5 million for Q1 2025.